Servier lifts worldwide exclusive licensing option on program in collaboration with Oncodesign Precision Medicine (OPM) in the treatment of Parkinson’s disease

  • CTA Regulatory Approval1 by the ANSMtwo and the CPP3 of the phase 1 program resulting from the collaboration between Servier and Oncodesign Precision Medicine for the development of an innovative treatment for Parkinson’s disease

  • Elimination of the exclusive worldwide license option, triggering payment by Servier of a historical payment of €7 million to Oncodesign Precision Medicine (OPM)

SURESNES, France & DIJON, France, September 26, 2022–(BUSINESSWIRE)–Regulatory news:

Servier, an international pharmaceutical group, and Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign (ALONC – FR0011766229) (Paris:ALONC) specializing in precision medicine, announce the exercise of the exclusive license option by Servier for its candidate: drug inhibitor of the target kinase LRRK2 (Leucine-Rich-Repeat Kinase 2), the result of its collaboration in Parkinson’s disease.

In March 2019, Servier and Oncodesign concluded a research and development collaboration on LRRK2 kinase inhibitors, from the Nanocyclix platform® belonging to OPM, as potential therapeutic agents for Parkinson’s disease. This collaboration builds on the complementary expertise of Servier and OPM in the field of neurodegenerative diseases and kinase inhibitors. In June 2021, the two companies announced the selection of a preclinical drug candidate. Servier anticipates starting a Phase 1 study in healthy volunteers before the end of 2022.

The exercise of the option triggers the payment by Servier of a payment milestone of 7 million euros to OPM. In total, Servier could pay OPM up to €320 million in R&D, regulatory and commercial milestone payments, to which royalties from future sales can be added.

Jan Hoflack, PhD, Chief Scientific Officer and CEO of Oncodesign and OPM says: “The approval of the CTA file by the ANSM and CPP, and Servier’s lifting of the license option precedes the first-in-human evaluation of the drug candidate, our key LRRK2 target inhibitor molecule. This drug candidate is the first molecule resulting from our Nanocyclix technology® to enter the clinic for a therapeutic evaluation. LRRK2 is a well-known kinase in the pharmaceutical industry since 2005. This kinase has been shown to be very difficult to target with inhibitors, but it is likely that it can slow the progression of Parkinson’s disease. It would be a great advance for patients suffering from this disease for which to date there are only symptomatic treatments. Our collaboration with Servier, started in 2019, has allowed us to discover a promising drug candidate in less than 4 years, thus demonstrating the maturity of the Nanocyclix technology.®, our expertise in the field of kinases, as well as Servier’s expertise in neuroscience, along with strong synergy and efficiency within the joint Servier/Oncodesign/OPM team. »

Philippe Genne, PhD, CEO and founder of Oncodesign and OPM explains : “I am very pleased with the rapid and fruitful progress of this collaboration with the Servier group, the company’s historical partner. More than ever, this term has a meaning here, because it is the first compound resulting from Oncodesign research to reach the clinical development stages. This project is also an important program in OPM’s growth strategy. We will be able to capitalize on this solid base for the promising development of this young and experienced Biotech. Undoubtedly, there is still a long way to go before transforming the candidate into a drug, but this step was crucial and heralds other successes to come for the benefit of patients. »

Ross Jeggo, PhD, Director of Servier’s Neuroscience and Immunoinflammation Therapeutic Area, says “The progress of the research and development program for this drug candidate in Parkinson’s disease is the result of the combined expertise of Servier and its partner Oncodesign. This collaboration demonstrates the Group’s desire to focus its research on diseases with high medical need, working closely with partners who share their knowledge and technologies to create innovation synergies and accelerate the discovery of therapeutic solutions for the benefit of patients. »

About Parkinson’s disease

Parkinson’s disease is the most common neurodegenerative disorder responsible for movement disorders, affecting 1% of the world’s population over 60 years of age.4. In total, around 170,000 people are treated in France, with around 25,000 new cases declared.5 every year. It is a chronic disease with progressive development of symptoms: slow movements, tremors, stiffness. Parkinson’s disease is characterized by a progressive loss of dopaminergic neurons and an accumulation of the protein α-synuclein in the brain. Current treatments, which are only symptomatic, are based on supplementing patients with dopamine to compensate for the loss of dopaminergic neurons and reduce motor disorders, with an efficacy that decreases over time. To date, there is no neuroprotective therapy capable of slowing down the progression of the disease. Modifying the course of the disease remains the main goal in the research and development of new treatments for Parkinson’s disease.

About the LRRK2 lens

Parkinson’s disease is considered an idiopathic disease, that is, without a clearly identified origin in the vast majority of cases. Pathogenic mutations of the LRRK2 protein are the most common monogenic form of Parkinson’s disease; a high level of activity of this protein is observed in these patients but also in idiopathic patients. The pathological features and clinical symptoms between an idiopathic patient and a patient carrying LRRK2 mutations are similar. LRRK2 is a multidomain protein, containing kinase and GTPase enzymatic activities, where pathogenic mutations are found. The inhibition of LRRK2 would therefore have a neuroprotective potential, capable of modifying the progression of Parkinson’s disease. Last May, the first Phase I and Phase Ib clinical trials with other LRRK2 inhibitors yielded very encouraging results. The collaborative program between Servier and OPM aims to develop a differentiating compound that meets the main medical needs of patients with Parkinson’s disease.

About Servier

Servier is an international pharmaceutical group governed by a Foundation. With a strong geographic presence and a turnover of €4.7 billion in 2021 achieved in 150 countries, Servier employs 21,800 people worldwide. Servier is an independent group that invests each year more than 20% of its originating sales in Research and Development. To accelerate therapeutic innovation for the benefit of patients, the Group is part of an open and collaborative innovation dynamic with academic partners, pharmaceutical groups and biotechnology companies. It also places the patient’s voice at the center of its activities, from research to support beyond medication.

A leader in cardiology, the Servier group aspires to become a renowned player and innovator in oncology. Its growth is based on a constant commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immunoinflammatory diseases. To promote access to care for all, the Servier group also offers a range of quality generic medicines that cover most pathologies. More information on the website:

Follow us on social networks: LinkedIn, Facebook, Twitter, instagram

About OPM

Oncodesign Precision Medicine (OPM), a subsidiary of Oncodesign, is a technology company specializing in precision medicine. Its mission is to provide innovative therapeutic and diagnostic solutions to treat the phenomena of therapeutic resistance and metastatic evolution of cancers. The patient is at the center of their thinking, of their truly unique innovation model, and of their investments. With a diversified portfolio of molecules and therapeutic targets, OPM positions itself as a discoverer of effective molecules against resistant and advanced cancers and other pathologies without a therapeutic solution. For OPM “working together is fundamental”, there can be no creation of values ​​without exchange, without dialogue. The creation of value resulting for us from reciprocity, that is, balanced and fair exchanges at all levels, whether between internal collaborators, as well as with our partners, therapists, patients, experts and investors. More information:

Forward Looking Statements

This document contains forward-looking statements and estimates regarding the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Certain of these statements, forecasts and estimates may be recognized by the use of words such as, but not limited to, “believes”, “anticipates”, “expects”, “expects”, “projects”, “plans”, “seeks”, “estimates”. ”, “can”, “will” and “continues” and other similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were believed to be reasonable when made, but may prove to be incorrect. Actual events are difficult to predict and may depend on factors beyond the Company’s control. Accordingly, the actual results, financial condition, performance or achievements of the Company, or the results of the industry, may differ materially from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. . Given these uncertainties, no statement is made. as to the accuracy or fairness of these forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the publication date of this document. The Company disclaims any obligation to update any such forward-looking statements, forecasts or estimates to reflect any change in the Company’s expectations with respect thereto, or any change in events, conditions or circumstances on which such forward-looking statements, forecasts or estimates are based. or estimates. Except as required by French law.

1 Clinical Trial Application
two National Drug Safety Agency
3 Committee for the Protection of Persons
4 Epidemiology of Parkinson’s disease. Neurol Clin. 2016 November; 34 (4): 955-965

See the source version on


Press contacts:
Sonya Brands | Such. +33 (0)1 55 72 40 21 |

Philip Gene
Such. : +33 (0)3 80 78 82 60

Investor Relations
Mathilde Bohin
Such. : +33 (0)1 44 71 94 95

media relations
rusty arthur
Such. : +33 (0)1 44 71 00 15

Leave a Comment

Your email address will not be published. Required fields are marked *